Listed

Denali Therapeutics Inc.

DNLINasdaqCIK 1714899HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$3.6m, Q2 FY2026
Operating income−$130.5m, Q2 FY2026
Net income−$127.6m, Q2 FY2026
Denali Therapeutics Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m1.3Revenue, Q3 FY2023, three months to 2023-09-30$1.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-06, accession 0001714899-24-000216.Report this figure0.0Revenue, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-05-07, accession 0001714899-24-000121.Report this figure0.0Revenue, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-08-01, accession 0001714899-24-000169.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-06, accession 0001714899-24-000216.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figurenot reported0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figurenot reportednot reportednot reported3.6Revenue, Q2 FY2026, three months to 2026-06-30$3.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure
Cost of revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reported0.0Cost of revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figurenot reportednot reportednot reported0.1Cost of revenue, Q2 FY2026, three months to 2026-06-30$93.0k. XBRL concept us-gaap:CostOfGoodsAndServicesSold. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure
Research and development$m89.7Research and development, Q3 FY2023, three months to 2023-09-30$89.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-06, accession 0001714899-24-000216.Report this figure108Research and development, Q4 FY2023, three months to 2023-12-31$107.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figure107Research and development, Q1 FY2024, three months to 2024-03-31$107.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-06, accession 0001714899-25-000105.Report this figure91.4Research and development, Q2 FY2024, three months to 2024-06-30$91.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-11, accession 0001714899-25-000170.Report this figure98.2Research and development, Q3 FY2024, three months to 2024-09-30$98.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figure99.8Research and development, Q4 FY2024, three months to 2024-12-31$99.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figure116Research and development, Q1 FY2025, three months to 2025-03-31$116.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure103Research and development, Q2 FY2025, three months to 2025-06-30$102.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure102Research and development, Q3 FY2025, three months to 2025-09-30$102.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figure97.9Research and development, Q4 FY2025, three months to 2025-12-31$97.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figure104Research and development, Q1 FY2026, three months to 2026-03-31$103.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure97.0Research and development, Q2 FY2026, three months to 2026-06-30$97.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure
Selling, general and administrative$mnot reportednot reportednot reportednot reportednot reportednot reportednot reported32.3Selling, general and administrative, Q2 FY2025, three months to 2025-06-30$32.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figurenot reportednot reportednot reported36.3Selling, general and administrative, Q2 FY2026, three months to 2026-06-30$36.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure
Operating income$m(114)Operating income, Q3 FY2023, three months to 2023-09-30−$113.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-06, accession 0001714899-24-000216.Report this figure(133)Operating income, Q4 FY2023, three months to 2023-12-31−$132.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figure(118)Operating income, Q1 FY2024, three months to 2024-03-31−$117.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-06, accession 0001714899-25-000105.Report this figure(117)Operating income, Q2 FY2024, three months to 2024-06-30−$116.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-11, accession 0001714899-25-000170.Report this figure(123)Operating income, Q3 FY2024, three months to 2024-09-30−$123.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figure(130)Operating income, Q4 FY2024, three months to 2024-12-31−$129.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figure(146)Operating income, Q1 FY2025, three months to 2025-03-31−$145.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure(135)Operating income, Q2 FY2025, three months to 2025-06-30−$135.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure(137)Operating income, Q3 FY2025, three months to 2025-09-30−$137.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figure(137)Operating income, Q4 FY2025, three months to 2025-12-31−$137.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figure(137)Operating income, Q1 FY2026, three months to 2026-03-31−$137.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure(131)Operating income, Q2 FY2026, three months to 2026-06-30−$130.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2023-11-07, accession 0001714899-23-000146.Report this figure0.0Income tax, Q4 FY2023, three months to 2023-12-31$30.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(99.4)Net income, Q3 FY2023, three months to 2023-09-30−$99.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-06, accession 0001714899-24-000216.Report this figure(119)Net income, Q4 FY2023, three months to 2023-12-31−$119.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figure(102)Net income, Q1 FY2024, three months to 2024-03-31−$101.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-06, accession 0001714899-25-000105.Report this figure(99.0)Net income, Q2 FY2024, three months to 2024-06-30−$99.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-11, accession 0001714899-25-000170.Report this figure(107)Net income, Q3 FY2024, three months to 2024-09-30−$107.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figure(115)Net income, Q4 FY2024, three months to 2024-12-31−$114.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figure(133)Net income, Q1 FY2025, three months to 2025-03-31−$133.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure(124)Net income, Q2 FY2025, three months to 2025-06-30−$124.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure(127)Net income, Q3 FY2025, three months to 2025-09-30−$126.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figure(129)Net income, Q4 FY2025, three months to 2025-12-31−$128.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figure(128)Net income, Q1 FY2026, three months to 2026-03-31−$128.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure(128)Net income, Q2 FY2026, three months to 2026-06-30−$127.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure
Diluted EPS$ per share(0.72)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.72 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-06, accession 0001714899-24-000216.Report this figurenot reported(0.68)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.68 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-06, accession 0001714899-25-000105.Report this figure(0.59)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.59 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-11, accession 0001714899-25-000170.Report this figure(0.63)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.63 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figurenot reported(0.78)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.78 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure(0.72)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.72 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure(0.74)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.74 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figurenot reported(0.69)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure(0.68)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.68 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure
Basic EPS$ per share(0.72)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.72 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-06, accession 0001714899-24-000216.Report this figurenot reported(0.68)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.68 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-06, accession 0001714899-25-000105.Report this figure(0.59)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.59 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-11, accession 0001714899-25-000170.Report this figure(0.63)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.63 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figurenot reported(0.78)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.78 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure(0.72)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.72 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure(0.74)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.74 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figurenot reported(0.69)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.69 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure(0.68)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.68 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure

Balance sheet

Cash and equivalents$201.5m, Q2 FY2026
Shareholders' equity$835.2m, Q2 FY2026
Denali Therapeutics Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m148Cash and equivalents, Q3 FY2023, at 2023-09-30$148.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-07, accession 0001714899-23-000146.Report this figure127Cash and equivalents, FY2023, at 2023-12-31$127.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-27, accession 0001714899-25-000066.Report this figure60.6Cash and equivalents, Q1 FY2024, at 2024-03-31$60.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-07, accession 0001714899-24-000121.Report this figure74.7Cash and equivalents, Q2 FY2024, at 2024-06-30$74.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-01, accession 0001714899-24-000169.Report this figure90.6Cash and equivalents, Q3 FY2024, at 2024-09-30$90.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-06, accession 0001714899-24-000216.Report this figure175Cash and equivalents, FY2024, at 2024-12-31$175.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001714899-26-000021.Report this figure56.9Cash and equivalents, Q1 FY2025, at 2025-03-31$56.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-06, accession 0001714899-25-000105.Report this figure141Cash and equivalents, Q2 FY2025, at 2025-06-30$141.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-11, accession 0001714899-25-000170.Report this figure91.0Cash and equivalents, Q3 FY2025, at 2025-09-30$91.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figure205Cash and equivalents, FY2025, at 2025-12-31$205.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure388Cash and equivalents, Q1 FY2026, at 2026-03-31$387.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure202Cash and equivalents, Q2 FY2026, at 2026-06-30$201.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure
Current assets$m1,143Current assets, Q3 FY2023, at 2023-09-30$1.14bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-07, accession 0001714899-23-000146.Report this figure1,064Current assets, FY2023, at 2023-12-31$1.06bn. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-27, accession 0001714899-25-000066.Report this figure974Current assets, Q1 FY2024, at 2024-03-31$973.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-07, accession 0001714899-24-000121.Report this figure928Current assets, Q2 FY2024, at 2024-06-30$928.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-01, accession 0001714899-24-000169.Report this figure869Current assets, Q3 FY2024, at 2024-09-30$868.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-06, accession 0001714899-24-000216.Report this figure864Current assets, FY2024, at 2024-12-31$864.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-26, accession 0001714899-26-000021.Report this figure879Current assets, Q1 FY2025, at 2025-03-31$878.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-06, accession 0001714899-25-000105.Report this figure935Current assets, Q2 FY2025, at 2025-06-30$934.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-11, accession 0001714899-25-000170.Report this figure883Current assets, Q3 FY2025, at 2025-09-30$882.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figure901Current assets, FY2025, at 2025-12-31$900.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure1,023Current assets, Q1 FY2026, at 2026-03-31$1.02bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure754Current assets, Q2 FY2026, at 2026-06-30$753.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure
Total assets$m1,237Total assets, Q3 FY2023, at 2023-09-30$1.24bn. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-07, accession 0001714899-23-000146.Report this figure1,154Total assets, FY2023, at 2023-12-31$1.15bn. XBRL concept us-gaap:Assets. 10-K filed 2025-02-27, accession 0001714899-25-000066.Report this figure1,581Total assets, Q1 FY2024, at 2024-03-31$1.58bn. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-07, accession 0001714899-24-000121.Report this figure1,503Total assets, Q2 FY2024, at 2024-06-30$1.50bn. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-01, accession 0001714899-24-000169.Report this figure1,454Total assets, Q3 FY2024, at 2024-09-30$1.45bn. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-06, accession 0001714899-24-000216.Report this figure1,374Total assets, FY2024, at 2024-12-31$1.37bn. XBRL concept us-gaap:Assets. 10-K filed 2026-02-26, accession 0001714899-26-000021.Report this figure1,271Total assets, Q1 FY2025, at 2025-03-31$1.27bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-06, accession 0001714899-25-000105.Report this figure1,166Total assets, Q2 FY2025, at 2025-06-30$1.17bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-11, accession 0001714899-25-000170.Report this figure1,056Total assets, Q3 FY2025, at 2025-09-30$1.06bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figure1,145Total assets, FY2025, at 2025-12-31$1.14bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure1,266Total assets, Q1 FY2026, at 2026-03-31$1.27bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure1,158Total assets, Q2 FY2026, at 2026-06-30$1.16bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure
Current liabilities$m71.2Current liabilities, Q3 FY2023, at 2023-09-30$71.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-07, accession 0001714899-23-000146.Report this figure78.0Current liabilities, FY2023, at 2023-12-31$78.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-27, accession 0001714899-25-000066.Report this figure82.6Current liabilities, Q1 FY2024, at 2024-03-31$82.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-07, accession 0001714899-24-000121.Report this figure74.5Current liabilities, Q2 FY2024, at 2024-06-30$74.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-01, accession 0001714899-24-000169.Report this figure87.1Current liabilities, Q3 FY2024, at 2024-09-30$87.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-06, accession 0001714899-24-000216.Report this figure102Current liabilities, FY2024, at 2024-12-31$102.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-26, accession 0001714899-26-000021.Report this figure91.9Current liabilities, Q1 FY2025, at 2025-03-31$91.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-06, accession 0001714899-25-000105.Report this figure91.1Current liabilities, Q2 FY2025, at 2025-06-30$91.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-11, accession 0001714899-25-000170.Report this figure90.1Current liabilities, Q3 FY2025, at 2025-09-30$90.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figure98.4Current liabilities, FY2025, at 2025-12-31$98.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure110Current liabilities, Q1 FY2026, at 2026-03-31$110.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure90.1Current liabilities, Q2 FY2026, at 2026-06-30$90.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure
Total liabilities$m118Total liabilities, Q3 FY2023, at 2023-09-30$118.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-07, accession 0001714899-23-000146.Report this figure123Total liabilities, FY2023, at 2023-12-31$123.0m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-27, accession 0001714899-25-000066.Report this figure126Total liabilities, Q1 FY2024, at 2024-03-31$125.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-07, accession 0001714899-24-000121.Report this figure116Total liabilities, Q2 FY2024, at 2024-06-30$115.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-01, accession 0001714899-24-000169.Report this figure136Total liabilities, Q3 FY2024, at 2024-09-30$135.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-06, accession 0001714899-24-000216.Report this figure144Total liabilities, FY2024, at 2024-12-31$144.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-26, accession 0001714899-26-000021.Report this figure149Total liabilities, Q1 FY2025, at 2025-03-31$148.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-06, accession 0001714899-25-000105.Report this figure139Total liabilities, Q2 FY2025, at 2025-06-30$139.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-11, accession 0001714899-25-000170.Report this figure129Total liabilities, Q3 FY2025, at 2025-09-30$129.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figure131Total liabilities, FY2025, at 2025-12-31$131.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure340Total liabilities, Q1 FY2026, at 2026-03-31$339.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure323Total liabilities, Q2 FY2026, at 2026-06-30$322.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure
Shareholders' equity$m1,118Shareholders' equity, Q3 FY2023, at 2023-09-30$1.12bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-06, accession 0001714899-24-000216.Report this figure1,031Shareholders' equity, FY2023, at 2023-12-31$1.03bn. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-26, accession 0001714899-26-000021.Report this figure1,455Shareholders' equity, Q1 FY2024, at 2024-03-31$1.46bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-11, accession 0001714899-25-000170.Report this figure1,387Shareholders' equity, Q2 FY2024, at 2024-06-30$1.39bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figure1,318Shareholders' equity, Q3 FY2024, at 2024-09-30$1.32bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figure1,230Shareholders' equity, FY2024, at 2024-12-31$1.23bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure1,123Shareholders' equity, Q1 FY2025, at 2025-03-31$1.12bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure1,027Shareholders' equity, Q2 FY2025, at 2025-06-30$1.03bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure926Shareholders' equity, Q3 FY2025, at 2025-09-30$926.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figure1,014Shareholders' equity, FY2025, at 2025-12-31$1.01bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure926Shareholders' equity, Q1 FY2026, at 2026-03-31$926.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure835Shareholders' equity, Q2 FY2026, at 2026-06-30$835.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure

Cash flow

Operating cash flow−$97.0m, Q2 FY2026
Capital expenditure$805.0k, Q2 FY2026
Denali Therapeutics Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(87.4)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$87.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-06, accession 0001714899-24-000216. Derived: 9-month figure less the 6-month figure.Report this figure(98.7)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$98.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figure(114)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$113.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-06, accession 0001714899-25-000105.Report this figure(91.2)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$91.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-11, accession 0001714899-25-000170. Derived: 6-month figure less the 3-month figure.Report this figure(59.1)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$59.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001714899-25-000193. Derived: 9-month figure less the 6-month figure.Report this figure(83.7)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$83.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figure(131)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$131.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure(75.3)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$75.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001714899-26-000097. Derived: 6-month figure less the 3-month figure.Report this figure(107)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$107.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001714899-25-000193. Derived: 9-month figure less the 6-month figure.Report this figure(98.5)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$98.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figure(131)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$131.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure(97.0)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$97.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001714899-26-000097. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m2.1Capital expenditure, Q3 FY2023, three months to 2023-09-30$2.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-06, accession 0001714899-24-000216. Derived: 9-month figure less the 6-month figure.Report this figure2.2Capital expenditure, Q4 FY2023, three months to 2023-12-31$2.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figure2.2Capital expenditure, Q1 FY2024, three months to 2024-03-31$2.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-06, accession 0001714899-25-000105.Report this figure4.8Capital expenditure, Q2 FY2024, three months to 2024-06-30$4.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-11, accession 0001714899-25-000170. Derived: 6-month figure less the 3-month figure.Report this figure3.9Capital expenditure, Q3 FY2024, three months to 2024-09-30$3.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001714899-25-000193. Derived: 9-month figure less the 6-month figure.Report this figure5.1Capital expenditure, Q4 FY2024, three months to 2024-12-31$5.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figure5.1Capital expenditure, Q1 FY2025, three months to 2025-03-31$5.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure4.3Capital expenditure, Q2 FY2025, three months to 2025-06-30$4.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001714899-26-000097. Derived: 6-month figure less the 3-month figure.Report this figure(1.4)Capital expenditure, Q3 FY2025, three months to 2025-09-30−$1.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001714899-25-000193. Derived: 9-month figure less the 6-month figure.Report this figure1.5Capital expenditure, Q4 FY2025, three months to 2025-12-31$1.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001714899-26-000021. Derived: 12-month figure less the 9-month figure.Report this figure2.5Capital expenditure, Q1 FY2026, three months to 2026-03-31$2.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure0.8Capital expenditure, Q2 FY2026, three months to 2026-06-30$805.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001714899-26-000097. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)187.31m, Q2 FY2026
Denali Therapeutics Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares123Diluted shares (weighted), Q3 FY2022, three months to 2022-09-30123,473,390 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-07, accession 0001714899-23-000146.Report this figure137Diluted shares (weighted), Q1 FY2023, three months to 2023-03-31136,524,528 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-07, accession 0001714899-24-000121.Report this figure141Diluted shares (weighted), Q2 FY2023, three months to 2023-06-30140,930,625 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-01, accession 0001714899-24-000169.Report this figure138Diluted shares (weighted), Q3 FY2023, three months to 2023-09-30137,644,534 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-06, accession 0001714899-24-000216.Report this figure149Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31149,404,188 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-06, accession 0001714899-25-000105.Report this figure169Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30168,831,329 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-11, accession 0001714899-25-000170.Report this figure169Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30169,456,988 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figure171Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31171,222,030 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure171Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30171,449,847 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure172Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30172,421,492 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001714899-25-000193.Report this figure187Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31186,636,978 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001714899-26-000064.Report this figure187Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30187,314,501 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure

Shares outstanding: 159.85mShares outstanding, period not labelled, at 2026-07-31159,847,403 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001714899-26-000097.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.